Cannabidiol for Bipolar Depression (CBD-BD)

NCT05867849 | Recruiting Phase 3 DMC

• 1 other identifier: H23-00105
• Study Type: interventional
• Target: 360
• Locations: 1 country
• Sites: 6

Brief Summary

Bipolar disorder (BD) is a lifelong condition characterized by recurrent episodes of depression and (hypo)mania. Periods of chronic and recurring depressive episodes are more common and can be severely disabling. Effective treatments exist; however, a significant portion of bipolar depressed patients do not respond to or have difficulty tolerating many of these interventions and thus look beyond established treatments to achieve symptom relief. Cannabidiol (CBD), a chemical from the Cannabis sativa plant, has shown to have some beneficial effects on mood symptoms in a few small studies which assessed its effects in other mental and physical health conditions, but no large studies have been conducted to assess its safety and efficacy in bipolar depression. Additionally, several clinical studies have shown CBD to be safe and tolerable. The primary objective of this study is to assess the effectiveness, safety and tolerability of cannabidiol in patients with bipolar depression (BD I or BD II) who have not responded to adequate trials with at least one first-line treatment for bipolar depression in comparison to those who will be treated with placebo. Placebo is an inactive substance that looks identical to the study medication but contains no therapeutic ingredient. This study is a randomized (like the flip of a coin), double-blind (you and the study team will not know which treatment arm you receive) study in which participants will receive either CBD or placebo added to their current treatment. Participants will have 5 clinical appointments and a phone appointment over a period of 10 weeks.

Conditions

Bipolar Disorder

Keywords

Cannabidiol; Bipolar Disorder; Bipolar Depression; Mood Disorder; CBD; Depression

Outcome Measures

Primary Outcomes (1)

• Improvement in depressive symptoms in bipolar patients treated with Cannabidiol vs Placebo adjunctive therapy

  The Montgomery Asberg Depression Rating Scale (MADRS) will be used to measure change in depressive symptoms from baseline to endpoint. Scores range from 0 to 60, and lower scores reflect better clinical outcomes.

  6 weeks

Secondary Outcomes (18)

• Response rates

  6 weeks

• Remission rates

  6 weeks

• Treatment-emergent manic/hypomanic events

  6 weeks

• Objective depressive symptoms

  6 weeks

• Subjective depressive symptoms

  6 weeks

Study Arms (2)

Cannabidiol

EXPERIMENTAL

Cannabidiol 200 - 600 mg / day added to current treatment for 6 weeks.

Drug: Cannabidiol

Placebo

PLACEBO COMPARATOR

Placebo added to current treatment for 6 weeks.

Other: Placebo

Interventions

Cannabidiol DRUG

Cannabinoid

Also known as: CBD

Cannabidiol

Placebo OTHER

Inactive substance

Placebo

Eligibility Criteria

• Age: 19 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females aged 19 to 70 years (inclusive).
• DSM-5 diagnosis of BD I or BD II, AND a current major depressive episode confirmed by MINI 7.0.2 .
• All patients must be taking either a mood stabilizer (i.e. lithium or valproate; lamotrigine monotherapy as a mood stabilizer is acceptable for BD II patients only and not for BD I) OR an atypical antipsychotic OR a combination of these (two mood stabilizers or a mood stabilizer plus an atypical antipsychotic), at therapeutic doses. Medications and therapeutic doses are: lithium, serum level 0.6-1.2 mEq/L; divalproex/sodium valproate, serum level 350-700 uM/L(45-125 mcg/ml); risperidone 2-6 mg/day; olanzapine 5-30 mg/day; quetiapine IR or XR 300-900 mg/day; aripiprazole 10-30 mg/day; cariprazine 1.5-6 mg/day; and ziprasidone 80-160 mg/day. Combinations of these medications as outlined above, or the combination of any of them with lamotrigine 100-400 mg daily, or the combination of a mood stabilizer plus asenapine 5-20 mg/day are also permitted.
• Have received a minimum of 6-weeks treatment at adequate doses for treatment of current depressive episode with at least one CANMAT recommended first-line treatment for bipolar I disorder (i.e. lithium, lamotrigine, lurasidone, or quetiapine either as monotherapy or adjunctive therapy), or at least one first or second-line treatment for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy).
• A MADRS score of ≥ 20 and a YMRS score of ≤ 12 (these cut off scores are standard in bipolar depression RCTs).
• Inpatient or outpatient status.
• All participants are required to agree to practice highly effective methods of contraception (i.e. hormonal contraceptives, intrauterine device or system, vasectomy and tubal ligation, or double barrier methods of contraception) OR agree to completely abstain from heterosexual intercourse. Females who do not have childbearing potential are required to be postmenopausal for at least 1 year before the screening visit (confirmed by an FSH test) OR surgically sterile.
• The capability of understanding, consenting to and complying with study requirements.
• All concomitant medication must be at a stable dose for two weeks prior to the randomization visit.

You may not qualify if:

• Current depressive episode greater than 12 months.
• A history of rapid cycling, defined as ≥ 4 mood episodes in the preceding 12 months.
• Current unstable or inadequately treated medical illness with the exception of current depression.
• Recently started taking a CANMAT-recommended treatment for the management of acute bipolar depressive episode, but has not had a trial for a minimum of 6 weeks with adequate doses.
• Recently (i.e. within the past 8 weeks) began structured psychotherapy (i.e. cognitive-behavioral therapy, interpersonal psychotherapy, family-focused therapy, or interpersonal and social rhythm therapy).
• Recently (i.e. within the past 8 weeks) started taking a stimulant medication. Concomitant treatment with stimulant medication is acceptable provided that the dose has been stable for a minimum of 8 weeks and is taken as prescribed by a physician.
• Current use of clozapine, tricyclic antidepressants, monoamine oxidase inhibitors, and first-generation antipsychotics.
• A history of non-response or intolerance to CBD.
• Current or past month daily use of CBD, or any product or drug that contains CBD. Occasional users will be included if they agree to refrain from using during the trial.
• A history of non-response to electroconvulsive therapy for the current depressive episode.
• A current diagnosis of other primary psychiatric disorders as assessed by a study investigator to be primary and causing greater impairment than BD.
• A lifetime history of a primary psychotic disorder (e.g. schizoaffective disorder, bipolar subtype) according to DSM-5 criteria.
• Patients who have met the DSM-5 criteria for a substance use disorder (except for nicotine or caffeine) within the past 6 months.
• Significant active suicidal ideation (as evidenced by MADRS suicide item ≥ 4).
• Pregnancy or lactation.

Sponsors & Collaborators

• University of British Columbia: lead

Study Sites (6)

UBC Mood Disorders Centre

Vancouver, British Columbia, V6T 1Z3, Canada

RECRUITING

St. Joseph's Healthcare

Hamilton, Ontario, L8N 3K7, Canada

RECRUITING

Providence Care Hospital

Kingston, Ontario, K7L 4X3, Canada

RECRUITING

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

NOT YET RECRUITING

Centre for Addiction and Mental Health (CAMH)

Toronto, Ontario, M6J1H4, Canada

NOT YET RECRUITING

Douglas Mental Health University Institute

Montreal, Quebec, H4H 1R3, Canada

NOT YET RECRUITING

MeSH Terms

Conditions

Bipolar Disorder; Mood Disorders; Depression

Interventions

Cannabidiol

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mental Disorders; Behavioral Symptoms; Behavior

Intervention Hierarchy (Ancestors)

Cannabinoids; Terpenes; Hydrocarbons; Organic Chemicals

Study Officials

• Lakshmi N Yatham, MBBS, MRCPsy

  University of British Columbia, Department of Psychiatry

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nazlin Walji, BSc

CONTACT

604-822-7294; nazlin.walji@ubc.ca

Shannon Reid, BA

CONTACT

604-822-8045; shannon.reid@ubc.ca

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Investigator

Study Record Dates

• First Submitted: May 9, 2023
• First Posted: May 22, 2023
• Study Start: October 15, 2023
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): December 1, 2030
• Last Updated: April 23, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (6)